Jardiance, marketed by Boehringer, is the first type 2 diabetes treatment approved with this additional indication and the only oral type 2 medicine shown in a clinical trial to provide a life-saving cardiovascular benefit.
Though there have been three adverse drug reactions reported till now, doctors say there may be likely additional cases about which they may be unaware of in the wake of a poor drug monitoring system.
To find an "affordable pricing (on a drug) for every segment of the population is not easy", he said, adding that in the US, the same drug is priced 20 times more.
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
